The Institute for Regenerative Medicine
Transformative Vision and Revolutionary Technology
Some science changes the way we live.
Some science transforms it. Regenerative medicine represents such a transformation – a new era in how we as humans will conquer or prevent disease as we work toward the ultimate goal of restoring health.
Our Director:
Andrew L. Pecora, M.D., FACP CPE
“Like no other time in our history, the enthusiasm surrounding regenerative medicine is now being matched with clinical deliverables.” - Andrew L. Pecora, M.D., FACP CPE
Tomorrow’s Clinical Breakthroughs… Today
The Institute for Regenerative Medicine will encompass not only the state-of-the-art laboratories and equipment required by scientists, but also the exam and treatment rooms required by physicians to apply it.
Structure and Governance
The Institute for Regenerative Medicine will benefit from the power of visionary leadership across not-for-profit and for-profit platforms.
The Institute for Regenerative Medicine
Faculty
Jason Butler, Ph.D.
Exploring the mechanisms by which vascular endothelial cells promote hematopoietic stem cell emergence, maintenance, and regeneration to develop therapeutic modalities to repair injured and aged hematopoietic systems.
Robert Korngold, Ph.D.
Dr. Korngold’s lab focuses on improvement of hematopoietic stem cell transplantation. In particular, we are interested in control of graft-versus-host disease development following allogeneic transplantation while enhancing graft-versus-tumor responses that can prevent a relapse of malignant disease. We are also focused on the utilization of T cell repertoire analysis as an indicator of outcomes post-transplant and the analysis of immune cell subsets to determine the effects of different immunotherapies on anti-tumor responses.
Yong Zhao MD, Ph.D.
Dr. Zhao discovered cord blood-derived multipotent stem cells (CB-SC) and successfully translated it into the FDA-approved clinical trial. Dr. Zhao invented Stem Cell Educator Therapy for the treatment of type 1 diabetes, type 2 diabetes, and other autoimmune diseases in humans. Currently, his lab is exploring the molecular and cellular mechanisms underlying Stem Cell Educator therapy to improve its clinical efficacy for the treatment of diabetes and autoimmune diseases.
